Editas Medicine, a genome editing company, has raised $120 million in an oversubscribed Series B financing. The round was led by Boris Nikolic M.D.; as part of the deal Dr. Nikolic has joined the company’s Board of Directors. Other investors in the round include Google Ventures, Khosla Ventures and Alexandria Venture Investments. Editas last raised a $43 million Series A financing at a $65 million valuation in November 2013.